Connect with us

Hi, what are you looking for?


Morgan Stanley just upgraded this large cap biotech stock

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now back to near its year-to-date high but a Morgan Stanley analyst says the stock is not done pleasing its investors yet.

Regeneron stock has another 20% upside

On Friday, Matthew Harrison upgraded the biotech name to “overweight” and announced a price objective of $851 a share that translates to a 20% upside on its previous close. The analyst wrote:

Overall, we now see REGN as the preferred large cap growth name supported by a range of products delivering durable revenues and an advancing oncology pipeline with the potential to diversify the base business.

Interestingly, the bullish call arrives only days after insiders were reported to have sold $16 million worth of the Regeneron stock.

Last month, the Nasdaq-listed firm reported its financial results for the second quarter that topped Wall Street estimates.

What will drive future growth?

A day earlier, Regeneron Pharmaceuticals Inc said “Eylea” – its treatment for retinal diseases showed promising results in a trial when used in high dosage.

Harrison expects it will continue to grow share moving forward and also sees potential in “Dupixent” to be a catalyst for the stock as well. He added:

Investors underappreciated the impact of the recent co-stim data and we believe oncology can be a multi-billion-dollar franchise. We see novel assets like bio-specifics and costimulatory antibodies as the key to driving major upside.

Dupixent is the company’s monoclonal antibody for atopic dermatitis. That Tarrytown-headquartered company is currently trading at a forward price-to-earnings multiple of under 16.

The post Morgan Stanley just upgraded this large cap biotech stock appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...


    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023